HealthLynked Corp Announces Chris Hall as New Chief Technology Officer

2 years ago

NAPLES, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK), a leader in healthcare technology innovation,…

Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China

2 years ago

A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024…

Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain

2 years ago

EAACI Congress 2024 EAACI Congress 2024 https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy…

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

2 years ago

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI…

Repligen Appoints Maggie A. Pax to Board of Directors

2 years ago

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors…

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

2 years ago

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials

2 years ago

ANN ARBOR, Mich., March 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"),…

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

2 years ago

PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

2 years ago

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements

2 years ago

$2.7M cash investments secured including $0.4M from Insiders $3.75M of Debt converted BOUCHERVILLE, Quebec, March 19, 2024 (GLOBE NEWSWIRE) --…